Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Alzheimers and Parkinsons

Aricept

Aricept

from
A$54.91
View product
Galantamine

Galantamine

from
A$109.84
View product

Understanding Alzheimer’s Disease

Alzheimer’s disease is a progressive neurodegenerative condition that affects memory, thinking, and behaviour. It accounts for 60-80% of dementia cases and primarily impacts older adults, though early-onset Alzheimer’s can occur in people under 65. The disease develops when proteins build up in the brain, forming plaques and tangles that damage and kill brain cells, leading to a decline in cognitive function over time.

In Australia, Alzheimer’s disease affects approximately 250,000 people, making it a significant health concern. The condition typically progresses through three stages: mild, moderate, and severe, with symptoms worsening over several years. Early signs include memory loss, difficulty with familiar tasks, and confusion about time and place. As the disease progresses, individuals may experience personality changes, increased confusion, and eventually, loss of independence.

Common medications available in Australia include donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl). These cholinesterase inhibitors help improve memory and thinking by increasing acetylcholine levels in the brain. Memantine (Ebixa) is another medication that works differently, helping to regulate glutamate activity. These medications don’t cure the disease but may slow symptom progression.

Recognising Parkinson’s Disease Symptoms

Parkinson’s disease is a chronic movement disorder affecting the central nervous system, characterised by tremor, rigidity, and bradykinesia (slowness of movement). It develops when neurons that produce dopamine deteriorate, disrupting the brain’s ability to control movement and coordinate motor functions. Approximately 80,000 Australians currently live with Parkinson’s disease, with thousands more diagnosed each year.

The primary symptoms include resting tremor (involuntary shaking), muscle stiffness, and difficulty initiating movement. Many people experience non-motor symptoms as well, such as sleep disturbances, depression, anxiety, and cognitive changes. Early diagnosis is important because treatment can help manage symptoms more effectively when started promptly.

Motor symptoms typically appear gradually and may be more noticeable on one side of the body initially. Secondary symptoms can include stooped posture, reduced facial expression, speech difficulties, and balance problems. Some individuals experience “freezing” episodes where they become temporarily unable to move, particularly when walking or changing direction.

Medication Options for Alzheimer’s Management

Managing Alzheimer’s disease in Australia involves both pharmacological and non-pharmacological approaches. Cholinesterase inhibitors are the first-line treatment for mild to moderate Alzheimer’s disease. Donepezil is available in 5mg and 10mg tablets and is typically taken once daily in the evening. Rivastigmine comes as capsules (1.5mg to 6mg) and as a transdermal patch, offering flexibility for patients with swallowing difficulties.

Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist suitable for moderate to severe Alzheimer’s disease. It’s available in 5mg, 10mg, and 20mg tablets, with dosing typically starting low and gradually increasing. Many patients take memantine alongside cholinesterase inhibitors for enhanced benefit.

In Australia, combination therapy using both medication types has shown promising results in slowing cognitive decline. Treatment decisions should be made in consultation with healthcare professionals, considering the patient’s stage of disease, overall health, and potential side effects. Regular monitoring helps assess medication effectiveness and adjust treatment as needed.

Treatment Approaches for Parkinson’s Disease

Levodopa (L-DOPA) remains the gold standard treatment for Parkinson’s disease motor symptoms in Australia. It’s usually combined with carbidopa or benserazide to prevent premature conversion and reduce side effects. Brands like Sinemet contain these combinations and are available in various strengths to suit individual needs. Dosing typically begins low and increases gradually as the body adjusts.

Dopamine agonists such as bromocriptine, pramipexole, and ropinirole directly stimulate dopamine receptors. These medications can be used alone in early disease or combined with levodopa as the condition progresses. Extended-release formulations provide steady symptom control throughout the day, reducing the need for frequent dosing.

Monoamine oxidase-B (MAO-B) inhibitors like selegiline and rasagiline help preserve remaining dopamine by blocking its breakdown. These are often used early in the disease course, potentially delaying the need for levodopa. Catechol-O-methyltransferase (COMT) inhibitors such as entacapone extend levodopa’s effectiveness by preventing its metabolism.

Living Well: Lifestyle and Support Strategies

Beyond medication, comprehensive management of Alzheimer’s and Parkinson’s diseases includes lifestyle modifications and support systems. For Alzheimer’s patients, cognitive stimulation through mental activities, maintaining social connections, and physical exercise can help preserve brain function. A healthy diet rich in antioxidants, omega-3 fatty acids, and vitamins may support brain health.

Parkinson’s patients benefit significantly from physiotherapy to maintain mobility, flexibility, and balance. Speech therapy helps address communication difficulties, whilst occupational therapy assists with daily living activities. Regular exercise, including walking, swimming, and tailored movement programmes, helps maintain motor function and overall fitness.

Both conditions require ongoing medical supervision to monitor disease progression and medication effectiveness. Australians have access to support organisations, community groups, and specialist services through the National Health and Medical Research Council. Family involvement and caregiver support are crucial, as both diseases significantly impact quality of life for patients and loved ones.

Key lifestyle strategies include:

  • Maintaining regular physical activity and exercise routines tailored to individual capabilities
  • Engaging in cognitive activities such as puzzles, reading, and learning new skills
  • Eating a balanced diet with emphasis on brain-healthy foods
  • Participating in social activities and maintaining meaningful relationships
  • Managing sleep patterns and establishing consistent routines
  • Seeking professional support from physiotherapists, speech pathologists, and occupational therapists
  • Attending support groups and educational programmes through disease-specific organisations

Australian Healthcare Services and Resources

Australia’s healthcare system provides comprehensive support for Alzheimer’s and Parkinson’s disease patients through Medicare, pathology services, and specialist neurologists. The Pharmaceutical Benefits Scheme (PBS) subsidises many medications for qualifying patients, making treatment more affordable. Aged care facilities and home support services assist those requiring additional help with daily activities.

Organisations like Dementia Australia and Parkinson’s Australia offer valuable resources, education programmes, and support groups for patients and carers. These services help individuals understand their diagnosis, access appropriate treatment, and connect with others facing similar challenges. Regular reviews with general practitioners ensure medications remain appropriate and side effects are managed effectively.

Australia’s investment in neurodegenerative disease research continues to advance understanding and treatment options. Clinical trials investigating new therapies are regularly available, offering hope for improved outcomes. Early diagnosis, prompt treatment initiation, and access to multidisciplinary care teams optimise management and quality of life for those living with these conditions across Australia.